IDEAYA Biosciences Inc
NASDAQ:IDYA

Watchlist Manager
IDEAYA Biosciences Inc Logo
IDEAYA Biosciences Inc
NASDAQ:IDYA
Watchlist
Price: 26.79 USD 0.71% Market Closed
Market Cap: 2.3B USD
Have any thoughts about
IDEAYA Biosciences Inc?
Write Note

IDEAYA Biosciences Inc
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

IDEAYA Biosciences Inc
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
IDEAYA Biosciences Inc
NASDAQ:IDYA
Selling, General & Administrative
-$35.4m
CAGR 3-Years
-24%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Selling, General & Administrative
-$14B
CAGR 3-Years
-5%
CAGR 5-Years
-15%
CAGR 10-Years
-9%
Gilead Sciences Inc
NASDAQ:GILD
Selling, General & Administrative
-$5.6B
CAGR 3-Years
-2%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Selling, General & Administrative
-$7.5B
CAGR 3-Years
-9%
CAGR 5-Years
-8%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Selling, General & Administrative
-$1.5B
CAGR 3-Years
-22%
CAGR 5-Years
-19%
CAGR 10-Years
-17%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Selling, General & Administrative
-$2.9B
CAGR 3-Years
-23%
CAGR 5-Years
-16%
CAGR 10-Years
-21%
No Stocks Found

IDEAYA Biosciences Inc
Glance View

Market Cap
2.3B USD
Industry
Biotechnology

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2019-05-23. The firm is focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead synthetic lethality product candidate, IDE397, is a clinical-stage methionine adenosyltransferase 2a (MAT2A) inhibitor for patients with solid tumors having methylthioadenosine phosphorylase (MTAP) deletions. Its clinical-stage product candidate, darovasertib (IDE196), is a protein kinase C (PKC), inhibitor that is being evaluated as a synthetic lethal combination therapy in patients having genetically defined cancers having GNAQ or GNA11 gene mutations. Its pipeline also includes preclinical research programs directed to synthetic lethality targets PARG, Pol Theta, Werner Helicase, and certain deoxyribonucleic acid (DNA) damage targets. The PARG program is for patients having tumors with a defined biomarker based on genetic mutations.

IDYA Intrinsic Value
11.02 USD
Overvaluation 59%
Intrinsic Value
Price

See Also

What is IDEAYA Biosciences Inc's Selling, General & Administrative?
Selling, General & Administrative
-35.4m USD

Based on the financial report for Sep 30, 2024, IDEAYA Biosciences Inc's Selling, General & Administrative amounts to -35.4m USD.

What is IDEAYA Biosciences Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-32%

Over the last year, the Selling, General & Administrative growth was -31%. The average annual Selling, General & Administrative growth rates for IDEAYA Biosciences Inc have been -24% over the past three years , -32% over the past five years .

Back to Top